

- R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Movement Disorder Society URTF (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. *Mov Disord* **23**, 2129-2170.
- [31] Johns MW (1991) A new method for measuring day-time sleepiness: The Epworth sleepiness scale. *Sleep* **14**, 540-545.
- [32] Walmsley R, Chan S, Smith-Byrne K, Ramakrishnan R, Woodward M, Rahimi K, Dwyer T, Bennett D, Doherty A (2020) Reallocating time from device-measured sleep, sedentary behaviour or light physical activity to moderate-to-vigorous physical activity is associated with lower cardiovascular disease risk. *medRxiv*, 2020.2011.2010.20227769.
- [33] Willetts M, Hollowell S, Aslett L, Holmes C, Doherty A (2018) Statistical machine learning of sleep and physical activity phenotypes from sensor data in 96,220 UK Biobank participants. *Sci Rep* **8**, 7961.
- [34] Feldman S, Ammar W, Lo K, Trepman E, van Zuylen M, Etzioni O (2019) Quantifying sex bias in clinical studies at scale with automated data extraction. *JAMA Netw Open* **2**, e196700.
- [35] Parkinsons Disease Digital Biomarker DREAM Challenge, <https://www.synapse.org/#!Synapse:syn8717496/wiki/422884>
- [36] Coran P, Goldsack JC, Grandinetti CA, Bakker JP, Bolognese M, Dorsey ER, Vasisht K, Amdur A, Dell C, Helfgott J, Kirchoff M, Miller CJ, Narayan A, Patel D, Peterson B, Ramirez E, Schiller D, Switzer T, Wing L, Forrest A, Doherty A (2019) Advancing the use of mobile technologies in clinical trials: Recommendations from the clinical trials transformation initiative. *Digit Biomark* **3**, 145-154.
- [37] Stephenson D, Badawy R, Mathur S, Tome M, Rochester L (2021) Digital progression biomarkers as novel endpoints in clinical trials: A multistakeholder perspective. *J Parkinsons Dis* **11**, S103-S109.
- [38] Bloem BR, Dorsey ER, Okun MS (2020) The coronavirus disease 2019 crisis as catalyst for telemedicine for chronic neurological disorders. *JAMA Neurol* **77**, 927-928.
- [39] Dorsey ER, Okun MS, Bloem BR (2020) Care, convenience, comfort, confidentiality, and contagion: The 5 C's that will shape the future of telemedicine. *J Parkinsons Dis* **10**, 893-897.
- [40] Miele G, Straccia G, Moccia M, Leocani L, Tedeschi G, Bonavita S, Lavorgna L, Digital Technologies, Web and Social Media Study Group of the Italian Society of Neurology (2020) Telemedicine in Parkinson's disease: How to ensure patient needs and continuity of care at the time of COVID-19 pandemic. *Telem J E Health* **26**, 1533-1536.

CORRECTED PROOF